These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20008118)

  • 1. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
    Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
    Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
    Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
    Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
    Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
    Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
    Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
    Janković MM; Kosanović MM
    Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
    Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
    Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
    Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
    Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
    Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
    Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum keratinocyte growth factor measurement in patients with prostate cancer.
    Mehta PB; Robson CN; Neal DE; Leung HY
    J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular forms of prostate-specific antigen and their clinical significance].
    Hilz H
    Urologe A; 1995 Jul; 34(4):275-82. PubMed ID: 7545841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.